Abstract
Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
CNS & Neurological Disorders - Drug Targets
Title: Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
Volume: 9 Issue: 6
Author(s): Maria Jose Diogenes and Tiago Fleming Outeiro
Affiliation:
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
Abstract: Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Export Options
About this article
Cite this article as:
Jose Diogenes Maria and Fleming Outeiro Tiago, Neurotrophic Factors as a Protective Strategy in Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237449
DOI https://dx.doi.org/10.2174/187152710793237449 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued) Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research Potential Biomarkers with Plasma Cortisol, Brain-derived Neurotrophic Factor and Nitrites in Patients with Acute Ischemic Stroke
Current Neurovascular Research Thiophene Ring-opening Reactions III: One-Pot Synthesis and Antitumor Activity of 1,3,4-Thiadiazoline–Benzothiazolo[3,2-<i>b</i>]pyridazine Hybrids†
Current Organic Synthesis Humanin; A Defender Against Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Repetitive Transcranial Magnetic Stimulation for ALS
CNS & Neurological Disorders - Drug Targets Importance of Zebrafish as an Efficient Research Model for the Screening of Novel Therapeutics in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry New Horizons in the Treatment of Neurological Disorders with Tailorable Gold Nanoparticles
Current Drug Metabolism Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Pharmacokinetics Prediction and Drugability Assessment of Diphenylheptanoids from Turmeric (Curcuma longa L)
Medicinal Chemistry The Journey From Metabolic Profiling to Biomarkers: The Potential of NMR Spectroscopy Based Metabolomics in Neurodegenerative Disease Research
Current Metabolomics Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation
CNS & Neurological Disorders - Drug Targets